NXTC Latest Headlines

Avere Therapeutics Secures $500 Million Private Placement—Fully Funds Development Through 2029 in NextCure Merger

Market Chameleon (Mon, 10-Aug 7:29 AM)

NextCure Shareholders Face Just 1.21% Ownership in New Avere Merger—Is This a Fair Deal?

Market Chameleon (Mon, 27-Jul 11:24 AM)

NextCure’s Transformation: Merger with Avere and $320M Financing Set Stage for Once-Weekly Oral IL-23 Therapy

Market Chameleon (Tue, 14-Jul 9:52 AM)

NextCure and Avere Merger Signals Ambitious Push Toward Once-Weekly Oral IL-23 Therapy

Market Chameleon (Tue, 14-Jul 7:05 AM)